Altaris, LLC (collectively with its managed funds, Altaris), has announced that it has entered into a definitive agreement to acquire the Life Sciences & Healthcare business (LS&H) from Clarivate plc (NYSE: CLVT). LS&H is comprised of the Cortellis and Decision Resources Group (DRG) portfolios and will operate as an independent company under Altaris’ ownership following the closing of the transaction. The transaction is expected to close in the second half of 2026, subject to the satisfaction of customary closing conditions and receipt of required regulatory approvals.
Latham & Watkins LLP represents the financing sources supporting the acquisition with a cross‑border team in the US and London led by Stelios Saffos, Global Chair of Latham’s Capital Markets and Hybrid Capital practices, and partners John Lister and Fergus Wheeler, with associates Rob Rogowski, Samantha Rudd, Judy Lee, Marco Zacchino, and Robert Dinan. Advice was also provided on tax matters by partner Bora Bozkurt, with associate Shiyi Parsons.
